Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P43026 (
lipopolysaccharide
)
62,215
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Interleukin-10
(
IL-10
) has been shown to be protective in models of sepsis. This protection is mediated in part by inhibition of monokine-dependent processes. Because
IL-10
can act on other cells to regulate inflammatory events, and because we have previously shown that clearance of inflammation is an active process, we examined whether
IL-10
could regulate processes of resolution during pulmonary inflammation induced by
lipopolysaccharide
(
LPS
) challenge. Administration of 1 microgram of
IL-10
with 6 micrograms
LPS
intratracheally to rats did not alter the time of onset or the magnitude of the initial response, as assessed by bronchoalveolar lavage (BAL) neutrophilia. However, the extent of the neutrophilia was markedly reduced at 18 h, and longer, after challenge. During ex vivo culture of cells obtained by BAL, neutrophils died by apoptosis and were engulfed by macrophages. Clearance of neutrophils was more rapid in the cultured BAL of rats treated with
IL-10
. In separate experiments,
IL-10
did not reduce survival rates of untreated human neutrophils, but did inhibit
LPS
-induced increases in survival in a dose-dependent fashion. Thus
IL-10
did not modulate the onset of, or peak of, neutrophil accumulation in response to
LPS
but did promote the clearance of recruited neutrophils in vivo. The mechanism of this anti-inflammatory action may be through the prevention of stimulated increases in neutrophil survival.
...
PMID:IL-10 enhances resolution of pulmonary inflammation in vivo by promoting apoptosis of neutrophils. 889 3
Interleukin-10
(
IL-10
) has been reported to be a negative cytokine for monocytes/macrophages. In the present study, we showed that
IL-10
is rather a positive cytokine and augments the growth and differentiation of human monocytes stimulated with macrophage colony-stimulating factor (M-CSF). Highly purified adherent human monocytes were cultured for 7 days with M-CSF in the presence or absence of
IL-10
. The number of recovered cells increased in the culture of monocytes with M-CSF +
IL-10
compared to the culture with M-CSF alone.
IL-10
alone was not enough to maintain the survival and differentiation of monocytes into macrophages. Morphological change cultured in M-CSF was also accelerated by addition of
IL-10
, and macrophages cultured in M-CSF +
IL-10
were more elongated compared to macrophages cultured with M-CSF alone. Binding of 125I-M-CSF to monocytes incubated with M-CSF +
IL-10
was about 1.7-fold higher than that to monocytes incubated with M-CSF alone. In accordance with the binding study, Northern blot analysis showed that the levels of the expression of c-fms, M-CSF receptor, mRNA in macrophages cultured in M-CSF +
IL-10
were higher than that in macrophages cultured in M-CSF alone. Macrophages cultured in M-CSF +
IL-10
expressed higher level of Fc gamma RI, II, III, and showed augmented Fc gamma receptor mediated phagocytosis. The former also produced higher level of H2O2 and O2-, when stimulated with zymosan, and of IL-6 when stimulated with
lipopolysaccharide
compared to the latter. These results taken together suggest that
IL-10
augments the growth and differentiation of human monocytes cultured in M-CSF.
...
PMID:Enhancement of macrophage colony-stimulating factor-induced growth and differentiation of human monocytes by interleukin-10. 897 7
Interleukin-10
(
IL-10
) is known to inhibit T cell-mediated responses.
IL-10
has also been shown to play an important pathogenetic role in allergic diseases. Glucocorticoid is known to inhibit the production and gene expression of many cytokines which induce inflammatory reactions. We examined the effect of dexamethasone on the gene expression and production of
IL-10
by human peripheral blood mononuclear cells (PBMCs) and monocytes. PBMCs and monocytes from 5 healthy volunteers were incubated with or without dexamethasone for 1 h, then stimulated with 5 micrograms/ml
lipopolysaccharide
(
LPS
). Gene expression and production of
IL-10
by human PBMCs were detected without stimulation and increased by
LPS
stimulation. Dexamethasone suppressed the gene expression and production of
IL-10
by
LPS
-stimulated PBMCs in a dose-dependent manner by 41.6 and 61.1% at 10(-6) M, respectively. Also in monocytes, the gene expression and production of
IL-10
were detected without stimulation, increased by
LPS
stimulation, and significantly suppressed by dexamethasone by 53.1 and 61.2% at 10(-6) M, respectively. This suppressive effect on
IL-10
gene expression was not so potent compared with its effect on cytokines such as IL-5. The suppression of
IL-10
production by glucocorticoid is suggested to be one of the important mechanisms by which glucocorticoids suppress allergic inflammation in the treatment of allergic diseases.
...
PMID:Dexamethasone suppressed gene expression and production of interleukin-10 by human peripheral blood mononuclear cells and monocytes. 898 Apr 59
Interleukin-10
(
IL-10
) has been found to inhibit
lipopolysaccharide
(
LPS
)-induced tissue factor expression by monocytes in vitro. To determine the effects of
IL-10
on
LPS
-induced activation of the hemostatic mechanisms in vivo, we performed a placebo-controlled, cross-over study of human endotoxemia. Two groups of eight volunteers were challenged with
LPS
(4 ng/kg) on two occasions: once in conjunction with placebo, and once with recombinant human
IL-10
(rhIL-10; 25 microg/kg). In group 1, placebo or rhIL-10 was given 2 minutes before
LPS
challenge, group 2 received placebo or rhIL-10 1 hour after
LPS
administration. Pretreatment with rhIL-10 reduced both
LPS
-induced activation of the fibrinolytic system (plasma concentrations of tissue type plasminogen activator, plasmin-alpha2-antiplasmin complexes, and D-dimer), and inhibition of fibrinolysis (plasma levels of plasminogen activator inhibitor 1), whereas posttreatment only inhibited the latter response. Both
IL-10
pre- and posttreatment attenuated activation of the coagulation system (plasma levels of prothrombin fragment F1 + 2 and thrombin-antithrombin complexes). These results indicate that rhIL-10, besides its well-described inhibitory effects on cytokine release, potently modulates the fibrinolytic system and inhibits the coagulant responses during endotoxemia.
...
PMID:Interleukin-10 inhibits activation of coagulation and fibrinolysis during human endotoxemia. 910 87
Interleukin-10
(
IL-10
) downmodulates phagocytic immune responses and accentuates humoral responses. Human neonates exhibit broad immune deficits that parallel actions of
IL-10
. We postulated that
IL-10
production would be diminished in neonatal blood cells. We found that
IL-10
production by
lipopolysaccharide
-stimulated peripheral blood mononuclear cells (PBMNCs) in vitro was greater by adult cells than by term cells and preterm cells. Additional studies were undertaken to identify mechanisms responsible for the developmental differences in
IL-10
gene expression.
IL-10
transcription was present in freshly isolated adult and neonatal cells in the absence of detectable levels of transcript. Transcription rates were not different between adult and neonatal cells.
IL-10
transcripts were approximately 40% more abundant in adult cells than in term cells and were consistent with differences in secreted protein; however, no differences were noted in mRNA stability.
IL-10
half-life was 60 minutes for both adult and term PBMNCs. We conclude that up-regulation of
IL-10
gene expression in PBMNCs is modulated at the post-transcriptional level, that
IL-10
protein production and mRNA content are greater in activated cells from adults compared with those from neonates, and that maturational differences in
IL-10
expression are not due to differences in transcription rate or mRNA stability. Maturational differences in
IL-10
expression might be due to differences in subpopulations of cytokine-producing cells or differences in nucleo-cytoplasmic transport.
...
PMID:Regulation of interleukin-10 gene expression: possible mechanisms accounting for its upregulation and for maturational differences in its expression by blood mononuclear cells. 916 53
Interleukin-10
inhibits T-lymphocyte activation and proliferation and
lipopolysaccharide
-induced monocyte production of proinflammatory cytokines. Fifty-four healthy volunteers received single doses of recombinant human interleukin-10 (1.0, 2.5, 5.0, 10, 25, or 50 micrograms/kg) or placebo by subcutaneous injection (randomized double-blind assignment). Clinical adverse events were infrequent at doses below 50 micrograms/kg (five of six subjects had mild flu-like syndrome). Mean serum interleukin-10 concentrations were dose related. The mean terminal-phase half-life ranged from 2.7 to 4.5 hours, and the apparent volume of distribution ranged from 0.70 to 1.35 L/kg. Hematologic changes included transient mild to moderate increases of neutrophil counts, decreases of lymphocyte counts, and a delayed decrease of platelet counts. Recombinant human interleukin-10 significantly suppressed production of the proinflammatory cytokines interleukin-1 beta and tumor necrosis factor-alpha by whole blood stimulated ex vivo with Escherichia coli
lipopolysaccharide
.
...
PMID:Pharmacodynamics of subcutaneous recombinant human interleukin-10 in healthy volunteers. 928 53
Neutrophils play a key role in the pathophysiology of septic multiple organ dysfunction syndrome (MODS) through excessive release of toxic granule components and reactive oxygen metabolites with consequent tissue destruction. The increase of senescent neutrophils during sepsis indicates a potential breakdown of autoregulatory mechanisms including apoptotic processes to remove activated neutrophils from inflammatory sites. Therefore, neutrophil apoptosis of patients with severe sepsis and its regulatory mechanisms were investigated. Spontaneous neutrophil apoptosis from patients with severe sepsis was significantly reduced in comparison to healthy individuals. Cytokines detected in the circulation during sepsis (tumor necrosis factor-alpha [TNF-alpha], interferon-gamma [IFN-gamma], granulocyte colony-stimulating factor [G-CSF], granulocyte-macrophage colony-stimulating factor [GM-CSF]) inhibited neutrophil apoptosis in both groups, though the effect was more distinct in neutrophils from healthy humans. Addition of
lipopolysaccharide
(
LPS
) to neutrophils from healthy humans markedly (P < .05) reduced apoptosis which was partially restored through addition of anti-TNF-antibody.
Interleukin-10
(
IL-10
) counteracted (P < .05) inhibition of neutrophil apoptosis induced by
LPS
, recombinant human (rh) TNF-alpha, rhIFN-gamma, rhG-CSF, and rhGM-CSF, whereas rhIL-4 or rhIL-13 were ineffective. Reduced neutrophil apoptosis during sepsis was concomitant with increased tyrosine phosphorylation, while
IL-10
markedly inhibited tyrosine phosphorylation in
LPS
-stimulated neutrophils. These results identify proinflammatory cytokines and
IL-10
as strong regulators of spontaneous neutrophil apoptosis during sepsis. Inhibition as well as acceleration of neutrophil apoptosis seems to be associated with alterations of signal transduction pathways.
...
PMID:Interleukin-10 counterregulates proinflammatory cytokine-induced inhibition of neutrophil apoptosis during severe sepsis. 934 17
Interleukin-10
(
IL-10
) limits inflammatory responses by inhibiting macrophage activation. In macrophages,
IL-10
activates Stat1 and Stat3. We characterized
IL-10
responses of the J774 mouse macrophage cell line, and of J774 cells expressing wild-type hIL-10R, mutant hIL-10R lacking two membrane-distal tyrosines involved in recruitment of Stat3 (hIL-10R-TyrFF), a truncated Stat3 (DeltaStat3) which acts as a dominant negative, or an inducibly active Stat3-gyraseB chimera (Stat3-GyrB). A neutralizing anti-mIL-10R monoclonal antibody was generated to block the function of endogenous mIL-10R.
IL-10
inhibited proliferation of J774 cells and of normal bone marrow-derived macrophages, but not J774 cells expressing hIL-10RTyrFF. Dimerization of Stat3-GyrB by coumermycin mimicked the effect of
IL-10
, and expression of DeltaStat3 blocked the anti-proliferative activity of
IL-10
. For macrophage de-activation responses, hIL10R-TyrFF could not mediate inhibition of
lipopolysaccharide
-induced TNFalpha, IL-1beta or CD86 expression, while DeltaStat3 did not interfere detectably with these
IL-10
responses. Thus signals mediating both anti-proliferative and macrophage de-activation responses to
IL-10
require the two membrane-distal tyrosines of IL-10R, but Stat3 appears to function only in the anti-proliferative response.
...
PMID:IL-10 inhibits macrophage activation and proliferation by distinct signaling mechanisms: evidence for Stat3-dependent and -independent pathways. 946 79
Interleukin-10
(
IL-10
) and tumor necrosis factor (TNF) exert key roles in some acute and chronic inflammatory diseases. In this study we investigated (1) the potency of different cAMP-elevating agents in enhancing
IL-10
synthesis, (2) the involvement of protein kinase A in this enhancement, and (3) the mutual dependence of cAMP-enhanced
IL-10
formation and cAMP-suppressed TNF synthesis. Rolipram, a specific phosphodiesterase inhibitor and cicaprost, a prostacyclin analogue, were applied as cAMP-elevating agents. The stable cAMP antagonist (Rp)-cAMPS was used to abrogate activation of protein kinase A. Human peripheral blood mononuclear cells were stimulated with
lipopolysaccharide
(
LPS
). TNF was quantified by radioimmunoassay,
IL-10
by enzyme-linked immunosorbent assay, and mRNA by reverse transcriptase-polymerase chain reaction. After
LPS
stimulation alone 253+/-45 pg/mL
IL-10
was synthesized, which increased to 644+/-117 pg/mL in the presence of 1 microM rolipram. (Rp)-cAMPS reversed this increase of
IL-10
formation. In the same samples, the
LPS
-stimulated production of TNF was markedly attenuated by rolipram or cicaprost. A kinetic analysis revealed a significant increase in TNF production before
IL-10
formation was detectable. These results demonstrate that (1) cAMP-elevating agents enhance
IL-10
synthesis and suppress TNF production; (2) these regulative functions of cAMP-elevating agents are mediated by activation of protein kinases A; (3) suppression of TNF synthesis by cAMP in the early phase is not mediated by endogenous
IL-10
. Taken together, rolipram and cicaprost exert a dual regulatory function by enhancing
IL-10
formation and attenuating TNF synthesis.
...
PMID:Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production. 946 79
Kupffer cells (KC) play a central role in the initiation and perpetuation of hepatic inflammation, which, if uncontrolled, can result in tissue damage, fibrosis, and cirrhosis.
Interleukin-10
(
IL-10
) can inhibit a range of macrophage functions. We hypothesized that the transcription, synthesis, and release of
IL-10
may influence the development of liver injury. Rat KC were activated in vitro with
lipopolysaccharide
(
LPS
), and expression of
IL-10
mRNA compared with IL-13 and IL-1beta by reverse-transcription polymerase chain reaction (RT-PCR). The effects of pretreatment with recombinant
IL-10
(rIL-10) on KC phagocytosis, production of superoxide (SO), and tumor necrosis factor (TNF-) were examined by fluorescent activated cell sorter (FACS), reduction of ferricytochrome C, and bioassay, respectively. Rats were administered intraperitoneal carbon tetrachloride (CCl4), and expression of
IL-10
mRNA and protein in vivo compared with IL-13 and IL-1beta by RT-PCR and immunoblotting. Results were correlated with histological inflammatory changes. Finally,
IL-10
gene-deleted (IL-10-/-) mice and wild-type (WT) controls were administered intraperitoneal CCl4 biweekly for up to 70 days, and the development of inflammation and fibrosis compared by scoring histological changes.
IL-10
mRNA was up-regulated early, both in KC in vitro and in whole liver in vivo, concurrent with that of IL-1beta.
IL-10
was able to inhibit KC production of both SO and TNF- in vitro, and this was achieved more effectively than IL-4 or IL-13; no such effects were seen on KC phagocytosis. After 70 days of treatment with CCl4,
IL-10
-/- mice showed significantly more severe fibrosis and exhibited higher hepatic TNF- levels than WT controls. These results suggest that
IL-10
synthesized during the course of liver inflammation and fibrosis may modulate KC actions, and influence subsequent progression of fibrosis.
...
PMID:Interleukin-10 expression and function in experimental murine liver inflammation and fibrosis. 982 39
<< Previous
1
2
3
4
5
6
7
8
9
Next >>